Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response

被引:32
作者
Yamada, Ryoko [1 ]
Hiramatsu, Naoki [2 ]
Oze, Tsugiko [1 ]
Urabe, Ayako [1 ]
Tahata, Yuki [1 ]
Morishita, Naoki [3 ]
Kodama, Takahiro [1 ]
Hikita, Hayato [1 ]
Sakamori, Ryotaro [1 ]
Yakushijin, Takayuki [4 ]
Yamada, Akira [5 ]
Hagiwara, Hideki [10 ]
Mita, Eiji [6 ]
Oshita, Masahide [7 ]
Itoh, Toshifumi [8 ]
Fukui, Hiroyuki [11 ]
Inui, Yoshiaki [12 ]
Hijioka, Taizo [13 ]
Inada, Masami [14 ]
Katayama, Kazuhiro [9 ]
Tamura, Shinji [3 ]
Inoue, Atsuo [4 ]
Imai, Yasuharu [15 ]
Tatsumi, Tomohide [1 ]
Hamasaki, Toshimitsu [16 ]
Hayashi, Norio [10 ]
Takehara, Tetsuo [1 ]
机构
[1] Osaka Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Rosai Hosp, Dept Gastroenterol & Hepatol, Sakai, Osaka, Japan
[3] Minoh City Hosp, Dept Gastroenterol & Hepatol, Mino, Japan
[4] Osaka Gen Med Ctr, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Sumitomo Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[6] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Natl Hosp, Osaka, Japan
[7] Osaka Police Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[8] Japan Community Hlth Care Org, Dept Gastroenterol & Hepatol, Osaka Hosp, Osaka, Japan
[9] Osaka Int Canc Inst, Dept Gastroenterol & Hepatol, Osaka, Japan
[10] Kansai Rosai Hosp, Dept Gastroenterol & Hepatol, Amagasaki, Hyogo, Japan
[11] Yao Municipal Hosp, Dept Gastroenterol & Hepatol, Yao, Japan
[12] Hyogo Prefectural Nishinomiya Hosp, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan
[13] Natl Hosp Org, Dept Gastroenterol & Hepatol, Osaka Minami Med Ctr, Kawachi Nagano, Japan
[14] Toyonaka City Hosp, Dept Gastroenterol & Hepatol, Toyonaka, Osaka, Japan
[15] Ikeda Municipal Hosp, Dept Gastroenterol & Hepatol, Ikeda, Osaka, Japan
[16] Natl Cerebral & Cardiovasc Ctr, Dept Gastroenterol & Hepatol, Dept Data Sci, Suita, Osaka, Japan
关键词
chronic hepatitis C; pegylated interferon; risk factor; hepatocellular carcinoma; direct-acting antivirals; EARLY TUMOR RECURRENCE; INTERFERON THERAPY; PLUS RIBAVIRIN; ALPHA; IMPACT;
D O I
10.1111/hepr.13310
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim In patients with chronic hepatitis C, hepatocellular carcinoma (HCC) occurs at a certain frequency, even if a sustained virologic response (SVR) is achieved by antiviral treatment. Old age, liver fibrosis, and high post-treatment alpha-fetoprotein (AFP) level are typical risk factors of post-SVR HCC. We examined whether the frequencies and factors of HCC in patients with an SVR achieved from interferon treatment changed. Methods Among patients prospectively registered for pegylated interferon and ribavirin treatment, 2021 with an SVR without HCC development during the treatment period were followed up. The mean observation period was 49.5 +/- 26.2 months. Results The multivariable Cox regression analysis showed that older age, diabetes mellitus, advanced liver disease, and higher post-treatment AFP level were the independent risk factors throughout the observation period. The annual occurrence rate of HCC was 0.74% in the third year, 0.54% in the fourth year, and 0.40% in the fifth year; it gradually decreased from the third year. Because the time course hazards for HCC changed at 48 months, we separately analyzed its risk factors before and after this change point. The multivariable Cox regression analysis showed that the four above-mentioned factors were significantly related to HCC development within 4 years. Conversely, the univariable Cox regression analysis only identified diabetes mellitus as a significant factor for HCC development after 4 years. Conclusion The frequency of HCC in hepatitis C patients who achieved an SVR from interferon treatment decreased during the observation period, and its risk factors changed between the early and late periods.
引用
收藏
页码:570 / 578
页数:9
相关论文
共 50 条
  • [41] Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment
    Ando, Yusuke
    Ishigami, Masatoshi
    Ishizu, Yoji
    Kuzuya, Teiji
    Honda, Takashi
    Hayashi, Kazuhiko
    Ishikawa, Tetsuya
    Nakano, Isao
    Hirooka, Yoshiki
    Goto, Hidemi
    HEPATOLOGY RESEARCH, 2018, 48 (03) : E240 - E251
  • [42] Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma
    Hsu, Yao-Chun
    Wu, Chun-Ying
    Lin, Jaw-Town
    SEMINARS IN ONCOLOGY, 2015, 42 (02) : 329 - 338
  • [43] Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response
    Muecke, Victoria T.
    Thomas, Dominique
    Muecke, Marcus M.
    Waidmann, Oliver
    Zeuzem, Stefan
    Sarrazin, Christoph
    Pfeilschifter, Josef
    Vermehren, Johannes
    Finkelmeier, Fabian
    Grammatikos, Georgios
    LIVER INTERNATIONAL, 2019, 39 (11) : 2174 - 2183
  • [44] Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
    Moon, Chansoo
    Jung, Kyu Sik
    Kim, Do Young
    Baatarkhuu, Oidov
    Park, Jun Yong
    Kim, Beom Kyung
    Kim, Seung Up
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (02) : 573 - 581
  • [45] Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Tada, Toshifumi
    Kumada, Takashi
    Toyoda, Hidenori
    Mizuno, Kazuyuki
    Sone, Yasuhiro
    Kataoka, Saki
    Hashinokuchi, Shinichi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (12) : 1982 - 1988
  • [46] The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen
    Innes, Hamish
    Barclay, Stephen T.
    Hayes, Peter C.
    Fraser, Andrew
    Dillon, John F.
    Stanley, Adrian
    Bathgate, Andy
    McDonald, Scott A.
    Goldberg, David
    Valerio, Heather
    Fox, Ray
    Kennedy, Nick
    Bramley, Pete
    Hutchinson, Sharon J.
    JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 646 - 654
  • [47] Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients
    Nirei, Kazushige
    Kanda, Tatsuo
    Masuzaki, Ryota
    Mizutani, Taku
    Moriyama, Mitsuhiko
    MEDICINA-LITHUANIA, 2021, 57 (08):
  • [48] Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C
    Takata, Kazuhide
    Ishii, Fuminori
    Uchida, Yotaro
    Fukuda, Hiromi
    Yamauchi, Ryo
    Umeda, Kaoru
    Tsuchiya, Naoaki
    Tanaka, Takashi
    Yokoyama, Keiji
    Morihara, Daisuke
    Takeyama, Yasuaki
    Shakado, Satoshi
    Sakisaka, Shotaro
    Hirai, Fumihito
    INTERNAL MEDICINE, 2020, 59 (15) : 1855 - 1860
  • [49] Hepatitis C virus and other risk factors in hepatocellular carcinoma
    Schiefelbein, E.
    Zekri, A. -R.
    Newton, D. W.
    Soliman, G. A.
    Banerjee, M.
    Hung, Ch-W.
    Seifeldin, I. A.
    Lo, A. -Ch
    Soliman, A. S.
    ACTA VIROLOGICA, 2012, 56 (03) : 235 - 240
  • [50] Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: A case control study
    Tomoda, Takeshi
    Nouso, Kazuhiro
    Sakai, Akiko
    Ouchida, Mamoru
    Kobayashi, Sayo
    Miyahara, Koji
    Onishi, Hideki
    Nakamura, Shinichiro
    Yamamoto, Kazuhide
    Shimizu, Kenji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (04) : 797 - 804